BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman has maintained a Market Perform rating on Neurocrine Biosciences (NASDAQ:NBIX) but has reduced the price target from $111 to $100.
November 10, 2023 | 8:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BMO Capital analyst Evan Seigerman maintains a Market Perform rating on Neurocrine Biosciences and lowers the price target from $111 to $100.
The reduction in the price target by BMO Capital suggests a less optimistic valuation of Neurocrine Biosciences, which could lead to a negative perception among investors and potentially a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100